| abstract |
The present invention relates to the treatment of diseases associated with IL-22 (e.g., inflammatory bowel disease (IBD) (e.g., ulcerative colitis (UC (e.g., moderate to severe UC)) and Crohn's disease (e.g., Crohn's disease (CD)) and graft-versus-host disease (GVHD) (e.g., acute or chronic GVHD)) methods, uses, and compositions (e.g., articles and kits). |